BTG Btg Plc

TIDMBTG

RNS Number : 6000M

BTG PLC

14 October 2016

BTG plc: Notice of Results

London, UK, 14 October 2016: BTG plc (LSE: BTG), the specialist healthcare company, announces that it will be releasing its unaudited interim results for the six months ended 30 September 2016 (the "Interim Results") on Thursday 15 November 2016.

For further information contact:

 
 BTG                                FTI Consulting 
 
 Andy Burrows, VP Corporate         Mo Noonan / Hanna Skeppner 
  & Investor Relations 
 +44 (0)20 7575 1741; Mobile: 
  +44 (0)7990 530 605               +44 (0)20 3727 1000 
 
 Stuart Hunt, Investor Relations 
  Manager 
 +44 (0)20 7575 1582; Mobile: 
  +44 (0)7815 778 536 
 
 Chris Sampson, Corporate 
  Communications Director 
 +44 (0)20 7575 1595; Mobile: 
  +44 (0)7773 251 178 
 

About BTG

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: www.btgplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORLLFSLIRLSLIR

(END) Dow Jones Newswires

October 14, 2016 07:46 ET (11:46 GMT)

Btg (LSE:BTG)
Historical Stock Chart
From Apr 2024 to May 2024

Btg (LSE:BTG)
Historical Stock Chart
From May 2023 to May 2024